Literature DB >> 2291880

Debrisoquine oxidation phenotype and susceptibility to lung cancer.

A R Boobis, D S Davies.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2291880      PMCID： PMC1368264          DOI： 10.1111/j.1365-2125.1990.tb03832.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  16 in total

1.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.

Authors:  E Steiner; L Bertilsson; J Säwe; I Bertling; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1988-10       Impact factor: 6.875

2.  Diurnal effects on debrisoquine hydroxylation phenotyping.

Authors:  E J Lee
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.

Authors:  N Caporaso; R B Hayes; M Dosemeci; R Hoover; R Ayesh; M Hetzel; J Idle
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

4.  Debrisoquine oxidation phenotype and susceptibility to lung cancer.

Authors:  C J Speirs; S Murray; D S Davies; A F Biola Mabadeje; A R Boobis
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

5.  Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.

Authors:  I Roots; N Drakoulis; M Ploch; G Heinemeyer; R Loddenkemper; T Minks; M Nitz; F Otte; M Koch
Journal:  Klin Wochenschr       Date:  1988

Review 6.  Genetic predisposition to lung cancer.

Authors:  M R Law
Journal:  Br J Cancer       Date:  1990-02       Impact factor: 7.640

7.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

8.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

Authors:  C J Speirs; S Murray; A R Boobis; C E Seddon; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

9.  The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.

Authors:  N Caporaso; L W Pickle; S Bale; R Ayesh; M Hetzel; J Idle
Journal:  Genet Epidemiol       Date:  1989       Impact factor: 2.135

10.  Debrisoquine metabolism and genetic predisposition to lung cancer.

Authors:  M R Law; M R Hetzel; J R Idel
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640
View more
  2 in total

1.  DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers.

Authors:  C Mura; S Panserat; M Vincent-Viry; M M Galteau; E Jacqz-Aigrain; R Krishnamoorthy
Journal:  Hum Genet       Date:  1993-10       Impact factor: 4.132

2.  Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer.

Authors:  F P Guengerich; W W Johnson; Y F Ueng; H Yamazaki; T Shimada
Journal:  Environ Health Perspect       Date:  1996-05       Impact factor: 9.031
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.